You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Ipsapirone
Ipsapirone is a selective 5-HT1A receptor agonist (Ki = 10 nM). Anxiolytic in vivo.
Technical Data for Ipsapirone
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Ipsapirone
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Ipsapirone
The following data is based on the product molecular weight 401.48. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||24.91 mL||124.54 mL||249.08 mL|
|0.5 mM||4.98 mL||24.91 mL||49.82 mL|
|1 mM||2.49 mL||12.45 mL||24.91 mL|
|5 mM||0.5 mL||2.49 mL||4.98 mL|
References for Ipsapirone
References are publications that support the biological activity of the product.
Maj et al (1987) Central action of ipsapirone, a new anxiolytic drug, on serotoninergic, noradrenergic and DArgic functions. J.Neural.Transm. 70 1 PMID: 2889795
Glaser and Traber (1985) Binding of the putative anxiolytic TVX Q 7821 to hippocampal 5-hydroxytryptamine (5-HT) recognition sites. Naunyn-Schmied.Arch.Pharmacol. 329 211
Traber et al (1984) Brain serotonin receptors as a target for the putative anxiolytic TVX Q 7821. Brain Res.Bull. 12 741 PMID: 6541079
If you know of a relevant reference for Ipsapirone, please let us know.
View Related Products by Product Action
Keywords: Ipsapirone, Ipsapirone supplier, Selective, 5-HT1A, agonists, Serotonin, Receptors, TVXQ7821, TVX, Q, 7821, 1869, Tocris Bioscience
2 Citations for Ipsapirone
Citations are publications that use Tocris products. Selected citations for Ipsapirone include:
Borroto-Escuela et al (2017) Existence of Brain 5-HT1A-5-HT2A Isoreceptor Complexes with Antagonistic Allosteric Receptor-Receptor Interactions Regulating 5-HT1A Receptor Recognition. ACS Omega 2 4779 PMID: 28920103
Rozeske et al (2011) Uncontrollable, but not controllable, stress desensitizes 5-HT1A receptors in the dorsal raphe nucleus. J Neurosci 31 14107 PMID: 21976495
Do you know of a great paper that uses Ipsapirone from Tocris? Please let us know.
Reviews for Ipsapirone
There are currently no reviews for this product. Be the first to review Ipsapirone and earn rewards!
Have you used Ipsapirone?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.